Japan Clears Merck's Gardasil To Ease HPV Vaccine Shortage; AstraZeneca, Astellas Also Gain Approvals
This article was originally published in PharmAsia News
Executive Summary
July kicks off a good start for the Japanese subsidiary of Merck & Co. Inc., known as Merck, Sharp & Dohme, with three new drug approvals from Japan's Ministry of Health, Labor and Welfare. Among them, cervical cancer vaccine Gardasil will largely benefit from a recently expanded Japanese government public coverage program for human papillomavirus vaccines
You may also be interested in...
Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference
In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the recent Morgan Stanley Global Healthcare Conference in New York ('Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference,' PharmAsia News, Sept. 22, 2011). For this profile, we zoom in on the Bank of America Merrill Lynch Global Healthcare Conference, held Sept. 15-16 in London.
Emerging Views On Emerging Markets: Bank of America Merrill Lynch Global Healthcare Conference
In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on the recent Morgan Stanley Global Healthcare Conference in New York ('Emerging Views On Emerging Markets: Morgan Stanley Global Healthcare Conference,' PharmAsia News, Sept. 22, 2011). For this profile, we zoom in on the Bank of America Merrill Lynch Global Healthcare Conference, held Sept. 15-16 in London.
AstraZeneca's Nexium, J&J's Simponi Lead Charge Of New Products To Receive Reimbursement Prices In Japan
TOKYO - A new round of drugs were cleared for market launch in Japan after the latest round of National Health Insurance price listings, and AstraZeneca PLC's blockbuster Nexium (esomeprazole), waning in the West but picking up speed in Asian markets, leads the new wave of products